Literature DB >> 14566013

Perlecan and tumor angiogenesis.

Xinnong Jiang1, John R Couchman.   

Abstract

Perlecan is a major heparan sulfate proteoglycan (HSPG) of basement membranes (BMs) and connective tissues. The core protein of perlecan is divided into five domains based on sequence homology to other known proteins. Commonly, the N-terminal domain I of mammalian perlecan is substituted with three HS chains that can bind a number of matrix molecules, cytokines, and growth factors. Perlecan is essential for metazoan life, as shown by genetic manipulations of nematodes, insects, and mice. There are also known human mutations that can be lethal. In vertebrates, new functions of perlecan emerged with the acquisition of a closed vascular system and skeletal connective tissues. Many of perlecan's functions may be related to the binding and presentation of growth factors to high-affinity tyrosine kinase (TK) receptors. Data are accumulating, as discussed here, that similar growth factor-mediated processes may have unwanted promoting effects on tumor cell proliferation and tumor angiogenesis. Understanding of these attributes at the molecular level may offer opportunities for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14566013      PMCID: PMC3957550          DOI: 10.1177/002215540305101101

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  203 in total

1.  Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene.

Authors:  E Arikawa-Hirasawa; W R Wilcox; A H Le; N Silverman; P Govindraj; J R Hassell; Y Yamada
Journal:  Nat Genet       Date:  2001-04       Impact factor: 38.330

2.  Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor.

Authors:  K Inoue; P Perrotte; C G Wood; J W Slaton; P Sweeney; C P Dinney
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

3.  A small peptide derived from Flt-1 (VEGFR-1) functions as an angiogenic inhibitor.

Authors:  D C Tan; R M Kini; S D Jois; D K Lim; L Xin; R Ge
Journal:  FEBS Lett       Date:  2001-04-13       Impact factor: 4.124

4.  Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo.

Authors:  J Luo; P Guo; K Matsuda; N Truong; A Lee; C Chun; S Y Cheng; M Korc
Journal:  Int J Cancer       Date:  2001-05-01       Impact factor: 7.396

5.  A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2.

Authors:  M Hagedorn; L Zilberberg; R M Lozano; P Cuevas; X Canron; M Redondo-Horcajo; G Gimenez-Gallego; A Bikfalvi
Journal:  FASEB J       Date:  2001-01-05       Impact factor: 5.191

6.  Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development.

Authors:  S M Plum; J W Holaday; A Ruiz; J W Madsen; W E Fogler; A H Fortier
Journal:  Vaccine       Date:  2000-12-08       Impact factor: 3.641

7.  Epidermal transformation leads to increased perlecan synthesis with heparin-binding-growth-factor affinity.

Authors:  P Tapanadechopone; S Tumova; X Jiang; J R Couchman
Journal:  Biochem J       Date:  2001-04-15       Impact factor: 3.857

8.  Nerve growth factor effects on human and mouse melanoma cell invasion and heparanase production.

Authors:  D Marchetti; D Menter; L Jin; M Nakajima; G L Nicolson
Journal:  Int J Cancer       Date:  1993-10-21       Impact factor: 7.396

9.  Products of the unc-52 gene in Caenorhabditis elegans are homologous to the core protein of the mammalian basement membrane heparan sulfate proteoglycan.

Authors:  T M Rogalski; B D Williams; G P Mullen; D G Moerman
Journal:  Genes Dev       Date:  1993-08       Impact factor: 11.361

10.  Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2).

Authors:  A Orr-Urtreger; M T Bedford; T Burakova; E Arman; Y Zimmer; A Yayon; D Givol; P Lonai
Journal:  Dev Biol       Date:  1993-08       Impact factor: 3.582

View more
  40 in total

1.  Glycosaminoglycans compositional analysis of Urodele axolotl (Ambystoma mexicanum) and Porcine Retina.

Authors:  So Young Kim; Joydip Kundu; Asher Williams; Anastasia S Yandulskaya; James R Monaghan; Rebecca L Carrier; Robert J Linhardt
Journal:  Glycoconj J       Date:  2019-04-08       Impact factor: 2.916

Review 2.  Amyloid accomplices and enforcers.

Authors:  Andrei T Alexandrescu
Journal:  Protein Sci       Date:  2004-12-02       Impact factor: 6.725

3.  Basement membrane and stroke.

Authors:  Yao Yao
Journal:  J Cereb Blood Flow Metab       Date:  2018-09-18       Impact factor: 6.200

4.  Perlecan modulates VEGF signaling and is essential for vascularization in endochondral bone formation.

Authors:  Muneaki Ishijima; Nobuharu Suzuki; Kentaro Hozumi; Tomoya Matsunobu; Keisuke Kosaki; Haruka Kaneko; John R Hassell; Eri Arikawa-Hirasawa; Yoshihiko Yamada
Journal:  Matrix Biol       Date:  2012-03-07       Impact factor: 11.583

Review 5.  The role of perlecan and endorepellin in the control of tumor angiogenesis and endothelial cell autophagy.

Authors:  Stephen Douglass; Atul Goyal; Renato V Iozzo
Journal:  Connect Tissue Res       Date:  2015-07-16       Impact factor: 3.417

Review 6.  Role of heparan sulfate in ocular diseases.

Authors:  Paul J Park; Deepak Shukla
Journal:  Exp Eye Res       Date:  2013-02-11       Impact factor: 3.467

7.  Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy.

Authors:  Mohammad R Noori-Daloii; Majid Momeny; Mehdi Yousefi; Forough Golsaz Shirazi; Mehdi Yaseri; Nasrin Motamed; Nazanin Kazemialiakbar; Saeed Hashemi
Journal:  Med Oncol       Date:  2010-07-02       Impact factor: 3.064

8.  Endorepellin affects angiogenesis by antagonizing diverse vascular endothelial growth factor receptor 2 (VEGFR2)-evoked signaling pathways: transcriptional repression of hypoxia-inducible factor 1α and VEGFA and concurrent inhibition of nuclear factor of activated T cell 1 (NFAT1) activation.

Authors:  Atul Goyal; Chiara Poluzzi; Chris D Willis; James Smythies; Adam Shellard; Thomas Neill; Renato V Iozzo
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

9.  In vitro and in vivo anticancer properties of a Calcarea carbonica derivative complex (M8) treatment in a murine melanoma model.

Authors:  Fernando S F Guimarães; Lucas F Andrade; Sharon T Martins; Ana P R Abud; Reginaldo V Sene; Carla Wanderer; Inés Tiscornia; Mariela Bollati-Fogolín; Dorly F Buchi; Edvaldo S Trindade
Journal:  BMC Cancer       Date:  2010-03-25       Impact factor: 4.430

10.  Differential expression of proteoglycans in tissue remodeling and lymphangiogenesis after experimental renal transplantation in rats.

Authors:  Heleen Rienstra; Kirankumar Katta; Johanna W A M Celie; Harry van Goor; Gerjan Navis; Jacob van den Born; Jan-Luuk Hillebrands
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.